Fallopian Tube Cancer Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Fallopian Tube Cancer Market Trends and Insights

Increasing Use of Antibody-Drug Conjugates

The U.S. Food and Drug Administration gave full approval to mirvetuximab soravtansine on March 22, 2024, for FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, and primary peritoneal cancer. The MIRASOL Phase 3 trial reported median overall survival of 16.5 months with mirvetuximab soravtansine and 12.7 months with chemotherapy, with a hazard ratio of 0.67 and a p-value of 0.0046. The trial also reported an objective response rate of 42% for the drug and 16% for chemotherapy. AbbVie received a positive CHMP opinion for ELAHERE in September 2024, supporting a route to broader European access. Daiichi Sankyo and AstraZeneca dosed the first patient in the DESTINY-Ovarian01 Phase 3 trial in December 2025, studying trastuzumab deruxtecan plus bevacizumab as first-line maintenance for HER2-expressing epithelial ovarian cancer, which includes fallopian tube cancer. The fallopian tube cancer market could therefore see treatment spending shift toward targeted regimens as these programs move through clinical development, especially when first-line maintenance studies establish an earlier role for antibody-drug conjugates and extend their use beyond the platinum-resistant setting. The pipeline also includes agents directed at TROP-2, NaPi2b, and B7-H4, which are being studied in trials that recruit patients with fallopian tube cancer. These programs seek to serve patients whose tumors are not suited to FRα-directed treatment, expanding the range of targets under evaluation.

Rising Biomarker-Guided Treatment Adoption

Biomarker selection has become part of routine treatment planning for many patients with epithelial ovarian and fallopian tube cancers. The ASCO guideline recommends germline sequencing of BRCA1 and BRCA2 through a multigene panel at diagnosis for all patients with epithelial ovarian cancer, including fallopian tube cancer. CMS Quality Measure #507 calls for germline genetic testing within 6 months of a fallopian tube cancer diagnosis as part of physician performance assessment. The NCCN framework also supports mirvetuximab soravtansine for appropriate patients with platinum-resistant disease and high FRα expression. These requirements make companion diagnostics important to access and prescribing, rather than a separate step after treatment selection. Better patient classification can also make clinical trial enrollment more precise, create more useful data for later targeted therapy programs, and support diagnosis growth within the fallopian tube cancer market as molecular results guide treatment eligibility. This feedback loop connects laboratory testing, treatment selection, and clinical development, rather than treating each activity as an isolated part of care.

Expansion of PARP Inhibitor Maintenance Therapy

PARP inhibitors have an established maintenance role after platinum-based treatment for advanced ovarian and fallopian tube cancer. GSK reported that niraparib plus dostarlimab met the primary progression-free survival endpoint in the FIRST-ENGOT-OV44 Phase 3 trial in first-line advanced ovarian cancer. The PRIMA final analysis showed a 5-year progression-free survival rate of 35% with niraparib and 16% with placebo in the HRD-positive population^{[1]González-Martín, A., et al., “Niraparib First-Line Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian Cancer: Final Overall Survival Results from the PRIMA/ENGOT-OV26/GOG-3012 Trial,” Penn State University Research Repository, pure.psu.edu.}. NICE recommended niraparib in February 2026 for routine maintenance use after first-line platinum-based chemotherapy in advanced epithelial high-grade ovarian, fallopian tube, and peritoneal cancer. Fuzuloparib reported a median progression-free survival of 29.9 months compared with 11.1 months for placebo in a final analysis reported in November 2024, with a hazard ratio of 0.58. These results support continued maintenance treatment adoption, although the fallopian tube cancer market remains dependent on appropriate patient selection and reimbursement. The overall survival result in unselected populations remains relevant to payer decisions because high crossover can complicate the interpretation of long-term outcomes. This places greater emphasis on HRD status and other biomarkers when health systems decide which patients should receive continued treatment. The same process supports the need for companion diagnostics alongside maintenance medicines.

Greater Integration of Genetic and Molecular Testing

International clinical guidance supports genetic counseling and germline testing for women with fallopian tube carcinoma regardless of age or family history. This increases the need for germline BRCA1 and BRCA2 testing, somatic testing, and broader genomic profiling. The ASCO guideline includes BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, and mismatch repair genes in the recommended multigene testing approach. A 2025 Nature Communications study profiled more than 100 human fallopian tubes using whole-genome bisulfite sequencing and proteomics, refining understanding of molecular changes before loss of heterozygosity. Blue Shield of California treats germline BRCA1 and BRCA2 testing as medically necessary for patients with advanced fallopian tube cancer under its medical policy. The fallopian tube cancer market benefits because testing is tied to therapy eligibility and remains relevant even when treatment competition changes. Genetic counseling, germline testing, and tumor profiling create a durable diagnostic need across the care pathway. This need applies before the first treatment, at recurrence, and when clinicians review potential options for maintenance therapy. The diagnostic role is therefore less dependent on one medicine or one treatment class than therapy revenue alone.

Low Disease Awareness and Delayed Diagnosis

Fallopian tube carcinoma is difficult to identify before surgery because its symptoms can resemble ovarian tumors, adnexal masses, and benign pelvic disease. This uncertainty may delay therapeutic intervention and lead to diagnosis after the disease has advanced. There is no reliable population screening test for fallopian tube cancer, which limits the ability to detect microscopic disease at an early stage. The lack of a standard early detection pathway can restrict curative-intent surgery volumes and leave more patients needing complex treatment. Provider misconceptions about the need for universal testing also remain a barrier to consistent genetic testing in community oncology settings. The fallopian tube cancer market is affected when patients reach specialized services late or do not receive the testing that could identify therapy options.

High Cost of Long-Term Precision Oncology

Long-term maintenance therapy with PARP inhibitors and antibody-drug conjugates can create a substantial cost burden for patients and healthcare systems. Mirvetuximab soravtansine requires FRα companion diagnostic testing and is administered every 3 weeks until disease progression or unacceptable toxicity. PARP inhibitor maintenance can continue for 24 months or longer, adding drug acquisition, monitoring, and clinical management costs. A 2026 Gynecologic Oncology study documented safety management needs, including thrombocytopenia-related dose modifications, among patients receiving first-line maintenance niraparib^{[2]“Real-World Safety Profile and Clinical Management of Patients with Epithelial Ovarian Cancer Who Received First-Line Maintenance Niraparib Therapy: Final Results from the 1NSPIRE Chart Review Study,” Gynecologic Oncology, doi.org.}. The limited overall survival benefit in unselected populations can lead payers to focus reimbursement on biomarker-confirmed groups. Health technology assessments, therefore, require manufacturers to demonstrate durable clinical value before access is broadened. This approach can reduce the reimbursable patient pool in parts of the fallopian tube cancer market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Offering: Diagnostics Accelerate as Therapeutic Options Broaden

Treatment accounted for 68.31% of the fallopian tube cancer market size by 2025. Surgery and platinum-based chemotherapy remained the foundation of initial management, while targeted therapy and immunotherapy were used in maintenance or recurrent settings. The diagnosis sub-segment is forecast to grow at a CAGR of 8.88% from 2026 to 2031. Molecular and genomic testing are becoming prerequisites for patients who may receive targeted therapies. The fallopian tube cancer industry is therefore seeing a larger role for testing before treatment decisions are made.

Antibody-drug conjugates and targeted therapies are changing the treatment mix even while chemotherapy retains the greatest treatment volume. NCCN materials include a Category 2B recommendation for trastuzumab deruxtecan in HER2-positive platinum-sensitive ovarian cancer, providing a clinical framework relevant to fallopian tube cancer. Germline and somatic testing are increasingly used alongside comprehensive genomic profiling. Imaging with MRI and PET remains relevant for presurgical staging. A 2025 case report found that transvaginal sonography identified an early-stage fallopian tube carcinosarcoma that enhanced CT had missed. The connection between therapeutic approvals and required companion diagnostics supports the faster growth of diagnosis in the fallopian tube cancer market.

By Disease Stage: Stage I Leads but Stage II Shows the Fastest Expansion

Stage I accounted for 45.24% of the fallopian tube cancer market share by disease stage in 2025. Its position reflects the number of surgically managed patients whose disease can be addressed with cytoreductive surgery. Earlier diagnosis can be prompted by watery vaginal discharge associated with the hydrops tubae profluens triad. Stage II is forecast to expand at a CAGR of 9.22% from 2026 to 2031. Reclassification of high-grade serous tumors to a fallopian tube origin increases recognition of Stage II cases that may previously have been coded as advanced ovarian cancer.

Perioperative chemotherapy is also being used more often in Stage II disease. Stage III remains the most treatment-intensive stage because patients commonly need combination regimens and maintenance PARP inhibitor therapy. Stage IV has the lowest incidence but can generate high per-patient treatment costs because of salvage regimens and antibody-drug conjugate protocols. The evidence base still draws heavily on FIGO systems originally developed for ovarian carcinoma. This shared framework helps clinicians classify disease, but restricts stage-specific natural history data for primary fallopian tube carcinoma. Updated FIGO criteria apply to a unified ovarian, fallopian tube, and peritoneal classification, which affects how the fallopian tube cancer market is tracked by stage^{[3]“Cancer of the Ovary, Fallopian Tube, and Peritoneum: 2025 Update,” International Journal of Gynecology and Obstetrics, doi.org.}.

By Histology: High-Grade Serous Carcinoma Dominates Across Both Share and Growth

High-Grade Serous Carcinoma held 69.14% of the share of the fallopian tube cancer market in 2025. The subtype is the predominant form of fallopian tube cancer and shares clinical and molecular features with BRCA-associated pelvic serous carcinomas. It is also forecast to grow at a CAGR of 9.82% from 2026 to 2031. This combination reflects the effects of diagnostic reclassification and broader biomarker-guided treatment coverage. The fallopian tube cancer industry is centered on this histology because it is most directly connected to current BRCA and FRα testing pathways.

Low-Grade Serous Carcinoma, Endometrioid Carcinoma, Clear Cell Carcinoma, Mucinous Carcinoma, and Carcinosarcoma together represented just over 30% of the histology base. Their molecular profiles can limit the use of BRCA-targeted and FRα-targeted treatments. Low-Grade Serous Carcinoma is linked to MEK pathway activation, which limits the role of PARP inhibitors and creates a need for MEK inhibitor approaches. Carcinosarcoma is associated with the poorest prognosis among the listed subtypes. A 2025 Phase 1/2 publication reported preliminary activity for DB-1305/BNT325 in solid tumors that included ovarian and fallopian tube cancer. Specialized pathology review remains important, including use of the SEE-FIM protocol for high-risk specimens.

By End User: Hospitals Anchor Volume; Specialty Clinics Lead Growth

Hospitals held 52.64% of end-user revenue in the fallopian tube cancer market size in 2025. Their position reflects access to surgery, infusion units, pathology laboratories, and multidisciplinary tumor boards. Cancer specialty centers also treat a significant share of high-acuity patients who require complex cytoreductive surgery or clinical trial enrollment. Specialty clinics are forecast to grow at a CAGR of 9.35% from 2026 to 2031. Oral PARP inhibitors and potential lower-complexity antibody-drug conjugate delivery support a move toward outpatient care.

Ambulatory Surgical Centers have an emerging role in early-stage surgical management as minimally invasive laparoscopic staging becomes more common in Stage I and Stage II disease. Outpatient care also offers a cost-containment route for payers and integrated health systems. AbbVie began a Phase 2 neoadjuvant study of mirvetuximab soravtansine in November 2025 for newly diagnosed FRα-expressing advanced-stage serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. The study examines a pathway in which antibody-drug conjugate treatment could precede surgery. GSK began a Phase IV niraparib study in India in April 2025 for patients with advanced or relapsed ovarian and fallopian tube cancer. These studies can inform use across specialty clinics and regional cancer centers in the fallopian tube cancer market.

Geography Analysis

North America held 38.61% of the global fallopian tube cancer market share in 2025. The region benefits from established regulation, high per-patient treatment spending, and extensive clinical trial activity. The United States remains the largest national setting because the FDA approved mirvetuximab soravtansine in March 2024, and CMS Quality Measure #507 supports genetic testing within 6 months of diagnosis. ASCO guidance and NCCN frameworks support multigene workup at diagnosis. Mexico remains less developed because formulary delays and lower oncology spending limit access to the biomarker-guided therapy and PARP inhibitors.

Europe follows North America in absolute contribution to the fallopian tube cancer market, with Germany, the United Kingdom, and France accounting for the largest national shares. The CHMP delivered a positive opinion on mirvetuximab soravtansine in September 2024, supporting potential EU-wide access. NICE recommended niraparib for routine NHS use in February 2026 after first-line platinum-based chemotherapy for advanced fallopian tube cancer. Asia-Pacific is the fastest-growing regional part of the fallopian tube cancer market, with a projected CAGR of 9.25% from 2026 to 2031. India, China, South Korea, and the Philippines are increasing oncology capacity, while China’s drug approval acceleration and reimbursement inclusion remain important near-term factors.

Middle East and Africa and South America are smaller but relevant parts of the fallopian tube cancer market. GCC countries and Brazil account for a disproportionate share of oncology spending within their regions. Cancer registries and private oncology networks are expanding in the GCC, although the absence of population-wide screening means many patients still present at Stage III or Stage IV. South Africa has the most developed oncology setting in Africa, but pathology capacity constrains timely molecular testing and accurate histological subtyping. Brazil is relevant to maintenance PARP inhibitor adoption because GSK began a Phase IV niraparib study there within its wider program. Argentina and the rest of South America remain behind on diagnostic infrastructure, but are improving access to platinum-based chemotherapy through public procurement programs.